Elizabeth Schackmann

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and <i>BRCA1</i>/<i>2</i> Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

Melinda L. Telli, Kristin C. Jensen, Shaveta Vinayak et al. · Journal of Clinical Oncology · 2015 · 228 citations · Full text

Medicine, Oncology, Pharmacology +16

Online Tool to Guide Decisions for<i>BRCA1/2</i>Mutation Carriers

Allison W. Kurian, Diego F. Muñoz, Peter Rust et al. · Journal of Clinical Oncology · 2012 · 91 citations · Full text

Medicine, Oncology, Surgery +17

Tumor <i>BRCA1</i> Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

Anosheh Afghahi, Kirsten M. Timms, Shaveta Vinayak et al. · Clinical Cancer Research · 2017 · 74 citations · Full text

Medicine, Oncology, Pharmacology +17

A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk

Shaveta Vinayak, Erich Schwartz, Kristin C. Jensen et al. · Breast Cancer Research and Treatment · 2013 · 40 citations · Full text

Medicine, Oncology, Pharmacology +10

Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations

Monique A. de Bruin, Ava Kwong, Benjamin A. Goldstein et al. · Familial Cancer · 2012 · 33 citations

Medicine, Genetics, Oncology +16